

09633958, 04 OCT 2000

525 Rec'd PCT/PTO 19 OCT 2000

FORM PTO-1390 (REV 12-29-99)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 2519US0P	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/673958	
INTERNATIONAL APPLICATION NO. PCT/JP99/02224		INTERNATIONAL FILING DATE April 27, 1999		PRIORITY DATE CLAIMED April 28, 1998	
TITLE OF INVENTION A Human Derived Immortalized Liver Cell Line					
APPLICANT(S) FOR DO/EO/US Masayoshi NANBA et al.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.					
3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).					
4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.					
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) *					
a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).					
b. <input type="checkbox"/> has been transmitted by the International Bureau.					
c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).					
6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).					
7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))					
a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).					
b. <input type="checkbox"/> have been transmitted by the International Bureau.					
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.					
d. <input type="checkbox"/> have not been made and will not be made.					
8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unexecuted) (3 separate declarations)					
10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11. to 16. below concern document(s) or information included:					
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.					
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.					
14. <input type="checkbox"/> A substitute specification.					
15. <input type="checkbox"/> A change of power of attorney and/or address letter.					
16. <input checked="" type="checkbox"/> Other items or information:					
1) Sequence Listing (Paper & Computer-readable copies)					
2) Sequence Listing Statement					
* This includes specification 36 total pages, including Claims 1-11(2 pgs), Abstract (1 pg), Drawings (5 pgs) and Sequence listing (3 pgs).					
Deposit OCT 19, 2000					
Express Mail No. EF074595390 US					

U.S. APPLICATION NO (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO		ATTORNEY'S DOCKET NUMBER	
09/673958		PCT/JP99/02224		2519USOP	
<div>17. <input checked="" type="checkbox"/> The following fees are submitted:</div> <div>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)\$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	11 - 20 =	0	X \$18.00	\$	0.00
Independent claims	6 - 3 =	3	X \$ 80 0	\$	240.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$	0.00
TOTAL OF ABOVE CALCULATIONS =				\$	1100.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$	1100.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	1100.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$	1100.00
				Amount to be refunded:	\$
				charged:	\$
<div>a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.</div> <div>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>500799</u> in the amount of \$ <u>1100 00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</div> <div>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>500799</u>. A duplicate copy of this sheet is enclosed.</div>					
<div>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</div> <div><div>SEND ALL CORRESPONDENCE TO: Customer No. 23,115</div><div style="text-align: right;"><div></div><div>SIGNATURE Philippe Y. Riesen</div><div>NAME 35,657</div><div>REGISTRATION NUMBER Date: October /7, 2000</div></div></div>					

09/673958

Attorney Docket No. 2519US0P
528 Rec'd PCT/PTO 19 OCT 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Masayoshi NANBA et al.
Serial No. :
Filed on :
Title : A Human Derived Immortalized Liver Cell Line
Attn: Box PCT

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Preliminary to examination please amend the above-identified application
as follows:

IN THE SPECIFICATION:

Page 1, first sentence, insert "This application is the National Stage of International
Application No. PCT/JP99/02224, filed on April 27, 1999."

Page 3, line 8, delete "characters" and substitute therefor --character--

Page 6, line 26, delete "is" and substitute therefor --are--

Page 7, line 20, delete "preferable" and substitute therefor --preferably--

Page 7, line 31, delete "characters" and substitute therefor --characteristics--

Page 11, line 20, delete "to" and substitute therefor --with--

REMARKS

The above amendments correct typographical and clerical errors and do not
constitute new matter. Entry of the above amendments prior to examination and
early action on the merits are respectfully requested.

Date: October 17, 2000

Respectfully submitted,



Philippe Y. Riesen, Reg. No. 35,657
Attorney for Applicants

Customer No. 23,115

5/PRTS

09673909/673958

1

528 Rec'd PCT/PTO 19 OCT 2000

Specification

A Human Derived Immortalized Liver Cell Line

5 Field of the Invention

The present invention relates to (1) a new immortalized hepatocyte culture of human (preferably human fetal) normal cell origin, (2) a method of producing said cell culture, (3) a screening method for a compound or a
10 salt thereof ① which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver, or ② which inhibits or promotes the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver, characterized by the use of said
15 cell culture, (4) a compound or a salt thereof ① which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver, or ② which inhibits or promotes the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the
20 liver, obtained using said screening method, and (5) an analytical method for enzymes involved in the metabolism of xenobiotics and/or endogenous substrates using said cell culture.

25 Background of the Invention

The hepatocyte possesses numerous physiological functions, including a very important function associated with the metabolism of what is called xenobiotics, wherein drugs, food additives, environmental pollutants and other
30 xenobiotics are metabolized to ready-to-excrete forms. As such, the xenobiotic-metabolizing function sometimes also leads to mutagenesis, toxicity manifestation or substance efficacy manifestation by xenobiotics, and is under very extensive research. For this reason, cultured hepatocytes
35 have been deemed not only to serve as a substitute for laboratory animals, as well as a quick, inexpensive and

accurate test method for investigating metabolism in the liver, but also to enable the preparation of what is called artificial liver to substitute for hepatic functions.

5 However, human normal hepatocytes as isolated from living tissue cannot be subcultured. Cells which can be established as cell cultures often lack the essential differentiating characters; the resulting cell culture often does not accurately reflect the functions of the
10 tissue to which they essentially belong. The class of enzymes involved in the metabolism of what is called xenobiotics in hepatocytes, in particular, lose their activity in a very short time in primary culture; no established cells have been found to sufficiently have the
15 essential characters (J. Dich et al., Hepatology, 8, 39-45 (1988)). Against this background, there has been a wide demand for hepatocytes which have the capability of metabolizing xenobiotics and which permit cultivation. A cell culture of the human liver is prepared by selecting
20 human tumor cells and exemplified by HepG2 (Aden et al., Nature, 282, 615-616, 1979). However, these cells are of tumor cell origin and do not represent immortalized normal cells. To immortalize normal cells, i.e., to allow normal cells to proliferate limitlessly, introduction of the T
25 antigen gene of SV (simian virus) 40 origin, for example, is commonly available. However, no immortalized cell cultures of human hepatic normal parenchymal origin are known to allow observation of the immortalization of normal parenchymal cells of the liver, more specifically enzyme
30 activity involved in the metabolism of xenobiotics, the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics, or the induction of expression of a gene encoding an enzyme involved in the metabolism of xenobiotics. In addition, serum components are essential
35 to media for cultivation of a large number of established cells. This necessity of serum components has been

problematic in that not only the stability of cultured cell properties is considerably impeded due to a lack of the qualitative stability of the serum but also the stable, accurate and inexpensive use of established cells is considerably hampered due to the very high price of the serum. Accordingly, proliferation of an established immortalized cell culture in a serum-free medium, while stably retaining its characters, would be industrially very beneficial.

Disclosure of the Invention

The object of the present invention is to provide a cell culture which is derived from human normal hepatocytes (preferably human normal hepatic parenchymal cells), which is capable of proliferating in serum-free complete synthetic media, and which allows the observation of metabolic functions specific to the human liver, more specifically of an enzyme activity involved in the metabolism of xenobiotics, or the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics, and to separate and produce said cell culture.

After extensive investigations in view of the above problem, the present inventors succeeded in establishing a cell culture which is derived from human normal hepatic parenchymal cells, which is capable of proliferating in serum-free complete synthetic media, and which allows the observation of metabolic functions specific to the human liver, more specifically of an enzyme activity involved in the metabolism of xenobiotics, or the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics, made further investigations based on this success, and developed the present invention.

Accordingly, the present invention relates to:
(1) an immortalized hepatocyte cell culture of human normal

cell origin having an enzyme activity involved in the metabolism of xenobiotics or the capability of expressing a gene encoding an enzyme involved in the metabolism of xenobiotics,

5 (2) the cell culture according to the above item (1) above wherein the enzyme activity is NADPH cytochrome P450 reductase activity, glucuronosyl transferase activity, ethoxyresorufine dealkylation activity, benzyloxyresorufine dealkylation activity, pentoxylresorufine dealkylation
10 activity, methoxyresorufine dealkylation activity, flavin monooxygenase activity, epoxy hydratase activity, sulfotransferase activity or glutathione S-transferase activity,

(3) the cell culture according to the above item (1) above
15 wherein the enzyme is NADPH cytochrome P450 reductase, NADPH cytochrome P450, flavin monooxygenase, epoxy hydratase, glucurosyl transferase, sulfotransferase or glutathione S-transferase,

(4) the cell culture according to the above item (3) above
20 wherein the NADPH cytochrome P450 is CYP1A1, CYP1A2 or CYP3A,

(5) the cell culture according to the above item (1) above wherein the cell culture is FERM BP-6328,

(6) a method of producing the cell culture according to the
25 above item (1) above, characterized by introduction of the T antigen gene of SV (simian virus) 40 origin into human normal hepatocytes,

(7) the production method according to the above item (6) above wherein the human normal hepatocytes are of human
30 fetal origin,

(8) a screening method for a compound or a salt thereof ① which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver, or ② which inhibits or promotes the expression of a gene encoding an
35 enzyme involved in the metabolism of xenobiotics in the liver, characterized by the use of the cell culture

according to the above item (1) above,

- (9) a compound or a salt thereof ① which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver, or ② which inhibits or promotes the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver, obtained by using the screening method according to the above item (8) above, (10) an analytical method for (a) enzymes involved in the metabolism of xenobiotics and/or endogenous substrates, (b) metabolic pathways for xenobiotics and/or endogenous substrates, (c) chemical structures of metabolites of xenobiotics and/or endogenous substrates, (d) inhibition of enzymes which metabolize xenobiotics and/or endogenous substrates, (e) promotion of the activity of enzymes which metabolize xenobiotics and/or endogenous substrates, (f) cytotoxicity due to the metabolism of xenobiotics and/or endogenous substrates, (g) genotoxicity due to the metabolism of xenobiotics and/or endogenous substrates, (h) carcinogenicity due to the metabolism of xenobiotics and/or endogenous substrates, (i) mutagenicity due to the metabolism of xenobiotics and/or endogenous substrates, (j) hepatotoxicity due to the metabolism of xenobiotics and/or endogenous substrates, or (k) hepatic action of xenobiotics and/or endogenous substrates, characterized by the use of the cell culture according to the above item (1) above, and (11) a method of preparing metabolites of xenobiotics and/or endogenous substrates.

Brief Description of the Drawings

Fig. 1 shows the results of the RT-PCR method performed in Example 3 (electrophoresis diagram), wherein Markers 2, 5, and 6 indicate respective DNA molecular weight markers (manufactured by Nippon Gene).

Fig. 2 shows the results of the RT-PCR method after addition of 3-methylcolanthrene (3-MC) performed in Example

4.

Fig. 3 shows the results of the RT-PCR method after addition of benzpyrene (BP) performed in Example 4.

5

Fig. 4 shows the results of the RT-PCR method after addition of phenobarbitone (PB) performed in Example 4.

Fig. 5 shows the results of the RT-PCR method after addition of dexamethasone (DEX) performed in Example 4.

10

Best Modes of Embodiment of the Invention

The term "normal cells", "normal hepatocytes", or "normal tissue" as used herein means cells or tissue which has not cancerated.

15

In addition, the term "metabolism of xenobiotics" means the metabolism of, for example, a drug, a food additive, an environmental pollutant, or the like, with preference given to drug metabolism etc.

20

The human normal hepatocytes (preferably human normal hepatic parenchymal cells) used can be separated from normal tissue of human adults, human fetuses, etc. (preferably human fetuses) by a well-established method known as collagenase perfusion. What is called primary cultured cells thus obtained are immortalized in accordance with various commonly known methods etc. Specifically, there may be mentioned a method focusing on the permanent proliferation of tissue which has cancerated wherein individual normal cells are immortalized by transformation with an oncogene introduced therein. Immortalized cell cultures thus established include, for example, subcultures of transformants of animal cells as obtained by introducing an oncogene, such as ras or c-myc, or an oncogene of a DNA type tumor virus, such as adenovirus EIA, SV (simian virus)

30

35

metabolism of xenobiotics include, for example, NADPH cytochrome P450 reductase activity, glucuronosyl transferase activity, mixed function oxidation (MFO) activities (e.g., ethoxyresorufine dealkylation activity, benzyloxyresorufine dealkylation activity, pentoxylresorufine dealkylation activity, methoxyresorufine dealkylation activity), flavin monooxygenase activity, epoxy hydratase activity, sulfotransferase activity, and glutathione S-transferase activity. Of these activities, NADPH cytochrome P450 reductase activity, glucuronosyl transferase activity, and mixed function oxidation (MFO) activities (e.g., ethoxyresorufine dealkylation activity, benzyloxyresorufine dealkylation activity, pentoxylresorufine dealkylation activity, methoxyresorufine dealkylation activity) are important; NADPH cytochrome P450 reductase activity, in particular, is considered as the most important enzyme activity from the viewpoint of functions in the metabolism of xenobiotics.

Enzymes involved in the liver-specific metabolism of xenobiotics include, for example, NADPH cytochrome P450 reductase, NADPH cytochrome P450, flavin monooxygenase, epoxy hydratase, glucuronosyl transferase, sulfotransferase, and glutathione S-transferase. Of these enzymes, NADPH cytochrome P450 represents the class of enzymes most important from the viewpoint of distribution and functions in the metabolism of xenobiotics. NADPH cytochrome P450 is a generic name for a large number of enzymic proteins; CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A (specifically CYP3A4, CYP3A5, CYP3A7 etc.), CYP2D6 etc. are known members of the NADPH cytochrome P450 class involved in the metabolism of xenobiotics in the human liver, with CYP1A1, CYP1A2, CYP3A etc. preferably used for the immortalized hepatocyte culture of the present invention. In addition, the functions of NADPH cytochrome P450 are also generically called the mixed function

oxidation (MFO) and are detected as ethoxyresorufine dealkylation activity, benzyloxyresorufine dealkylation activity, pentoxylresorufine dealkylation activity, methoxyresorufine dealkylation activity etc. Furthermore, the presence of NADPH cytochrome P450 reductase is essential to the expression of the MFO functions of the NADPH cytochrome P450 protein; this enzyme can also be classified as an enzyme which metabolizes xenobiotics.

In addition, a large number of xenobiotic-metabolizing enzymes are known to be induced under particular conditions. Well-known examples of this induction include the effects of polycyclic aromatic compounds such as benzpyrene, benzanthrane, 3-methylcholanthrene and dioxin on the expression of CYP1A1 and CYP1A2, the effects of phenobarbital and phenobarbitone on the induction of CYP2B (e.g., CYP2B6), and the effects of rifampicin, dexamethasone, phenytoin and phenylbutazone on the induction of CYP3A (C.G. Gibson et al., Shinpan Seitaiibutsu no Taishagaku, Kodansha, 1995).

The immortalized hepatocyte culture of human normal cell origin of the present invention can be used to screen for compounds having therapeutic/preventive effects on diseases associated with abnormalities of the metabolism of xenobiotics in the liver (e.g., hepatic insufficiency) because it has ① an enzyme activity involved in the metabolism of xenobiotics in the liver or ② the capability of expressing a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver.

Accordingly, the present invention also provides a screening method for a compound or a salt thereof ① which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver, or ② which inhibits or promotes the expression of a gene encoding an

enzyme involved in the metabolism of xenobiotics in the liver, characterized in that the test compound is brought into contact with the immortalized hepatocyte culture of human normal cell origin of the present invention, and that
5 observations/measurements are made of changes in ① an enzyme activity involved in the metabolism of xenobiotics in the liver or ② the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver.

10

Test compounds include, for example, peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, and plasma; these compounds may be
15 new compounds or commonly known compounds.

Specifically, the immortalized hepatocyte culture of human normal cell origin of the present invention can be treated with the test compound and compared with an intact
20 control immortalized hepatocyte culture of human normal cell origin to evaluate the therapeutic/preventive effects of the test compound with changes such as those in ① an enzyme activity involved in the metabolism of xenobiotics in the liver or ② the expression of a gene encoding an
25 enzyme involved in the metabolism of xenobiotics in the liver, in said immortalized hepatocyte culture of human origin serving as indices.

Being selected from among the test compounds
30 described above by using the screening method of the present invention, a compound obtained can be used as a safe therapeutic/preventive or other pharmaceutical of low toxicity for diseases associated with abnormalities of the metabolism of xenobiotics in the liver (e.g., hepatic
35 insufficiency) because it has therapeutic/preventive effects on such diseases. Furthermore, a compound

derivatized from the aforementioned compound obtained by screening can also be used similarly.

A compound obtained by said screening method may have
5 formed a salt. Said salt is exemplified by salts with
physiologically acceptable acids (e.g., inorganic acids,
organic acids), bases (e.g., alkali metals), etc., with
preference given to physiologically acceptable acid adduct
salts. Such salts include, for example, salts with
10 inorganic acids (e.g., hydrochloric acid, phosphoric acid,
hydrobromic acid, sulfuric acid) and salts with organic
acids (e.g., acetic acid, formic acid, propionic acid,
fumaric acid, maleic acid, succinic acid, tartaric acid,
citric acid, malic acid, oxalic acid, benzoic acid,
15 methanesulfonic acid, benzenesulfonic acid).

A pharmaceutical containing a compound obtained by
said screening method or a salt thereof can be produced by
a commonly known production method or a method based
20 thereon. The preparations thus obtained can be used to,
for example, humans or mammals (e.g., rats, mice, guinea
pigs, rabbits, sheep, swine, bovines, horses, cats, dogs,
monkeys) because they are safe and of low toxicity.

25 Varying depending on target disease, subject of
administration, route of administration, etc., the dose of
said compound or a salt thereof is normally about 0.1 to
about 100 mg per day, preferably about 1.0 to about 50 mg,
and more preferably about 1.0 to about 20 mg, based on the
30 compound, for example, when it is orally administered to an
adult (assuming 60 kg body weight) for the purpose of
treating hepatic insufficiency. In the case of non-oral
administration, although the dose of said compound per
administration varies depending on target disease, subject
35 of administration, etc., it is advantageous to administer
said compound at about 0.01 to about 30 mg per day,

preferably about 0.1 to about 20 mg, and more preferably about 0.1 to about 10 mg, by intravenous injection, for example, when it is administered in the form of an injection to an adult (assuming 60 kg) for the purpose of
5 treating hepatic insufficiency. For other animals, doses converted per 60 kg may be administered.

Examples of dosage forms for the aforementioned preparations include, for example, tablets (including
10 sugar-coated tablets and film-coated tablets), pills, capsules (including microcapsules), granules, fine subitiae, powders, syrups, emulsions, suspensions, injectable preparations, inhalants, and ointments. These preparations are prepared in accordance with commonly known methods
15 (e.g., methods listed in the Japanese Pharmacopoeia).

In such preparations, the content of a compound obtained by the screening method described above or a salt thereof varies depending on the form of the preparation but
20 is normally 0.01 to 100% by weight, preferably 0.1 to 50% by weight, and more preferably 0.5 to 20% by weight, relative to the weight of the entire preparation.

Specifically, tablets can be produced by granulating
25 a pharmaceutical as is, or in a uniform mixture with an excipient, a binder, a disintegrant or other appropriate additives, by an appropriate method, then adding a lubricant etc., and subjecting the mixture to compressive shaping, or by subjecting to direct compressive shaping a
30 pharmaceutical as is, or in a uniform mixture with an excipient, a binder, a disintegrant or other appropriate additives, or subjecting to compressive shaping previously prepared granules as is, or in a uniform mixture with appropriate additives. These tablets may incorporate
35 coloring agents, correctives etc. as necessary, and may be coated with appropriate coating agents.

Injectable preparations can be produced by dissolving, suspending or emulsifying a given amount of a pharmaceutical in an aqueous solvent such as water for injection, physiological saline or Ringer's solution, or a non-aqueous solvent such as a vegetable oil, and diluting to a given amount, or transferring a given amount of a pharmaceutical into a container for injection and sealing the container.

Useful carriers for oral preparations are substances in common use in the field of pharmaceutical formulations, including starch, mannitol, crystalline cellulose, and carboxymethylcellulose sodium. Useful carriers for injection include, for example, distilled water, physiological saline, glucose solutions, and infusion fluids. Other additives in ordinary use in pharmaceutical preparations may also be used as necessary.

Furthermore, the present invention relates to (a) an analytical method for enzymes involved in the metabolism of xenobiotics and/or endogenous substrates, (b) an analytical method for metabolic pathways for xenobiotics and/or endogenous substrates, (c) an analytical method for chemical structures of metabolites of xenobiotics and/or endogenous substrates, (d) a method of preparing metabolites of xenobiotics and/or endogenous substrates, (e) an analytical method for the inhibition of enzymes which metabolize xenobiotics and/or endogenous substrates, (f) an analytical method for the promotion of the activity of enzymes which metabolize xenobiotics and/or endogenous substrates, (g) an analytical method for the detection of cytotoxicity due to the metabolism of xenobiotics and/or endogenous substrates, (h) an analytical method for the detection of genotoxicity due to the metabolism of xenobiotics and/or endogenous substrates, (i) an analytical

method for the expression of carcinogenicity due to the metabolism of xenobiotics and/or endogenous substrates, (j) an analytical method for mutagenicity due to the metabolism of xenobiotics and/or endogenous substrates, (k) an analytical method for the expression of hepatotoxicity due to the metabolism of xenobiotics and/or endogenous substrates, or (l) an analytical method for the hepatic action of xenobiotics and/or endogenous substrates, characterized by the use of the aforementioned immortalized hepatocyte culture of human normal cell origin. The methods (a) through (l) above are described below.

(a) Analytical method for enzymes involved in the metabolism of xenobiotics and/or endogenous substrates:

For example, by analyzing the structural changes in xenobiotics and/or endogenous substrates caused by exposure of the test substance to immortalized hepatocytes of human normal cell origin, it is possible to analyze the enzymes involved in the metabolism of the xenobiotics and/or endogenous substrates (J.L. Napoli et al., Methods in Enzymology, Vol. 206, pp. 491-501, Ed. by M.R. Waterman et al., Academic Press, 1991; H.K. Kroemer et al., Methods in Enzymology, Vol. 272, pp. 99-198, Ed. by M.R. Waterman et al., Academic Press, 1996). Specifically, such analyses include the identification of enzymes involved in the metabolism of xenobiotics and/or endogenous substrates by analyzing the structural changes in the xenobiotics and/or endogenous substrates due to exposure of the test substance to immortalized hepatocytes of human normal cell origin using inhibitors/antagonists of various enzymes or neutralizing antibodies against various enzymes, and the analysis of enzyme reaction mechanisms and substrate specificity by analyzing the structural changes in xenobiotics and/or endogenous substrates due to exposure of the test substance to cells.

Test substances include, for example, peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts and plasma; these compounds may be
5 new compounds or commonly known compounds.

(b) Analytical method for metabolic pathways for xenobiotics and/or endogenous substrates:

For example, by analyzing the structural changes in
10 xenobiotics and/or endogenous substrates caused by exposure of the test substance to immortalized hepatocytes of human normal cell origin, it is possible to analyze the metabolic pathways for the xenobiotics and/or endogenous substrates (J.L. Napoli et al., Methods in Enzymology, Vol. 206, pp.
15 491-501, Ed. by M.R. Waterman et al., Academic Press, 1991; H.K. Kroemer et al., Methods in Enzymology, Vol. 272, pp. 99-198, Ed. by M.R. Waterman et al., Academic Press, 1996).

Useful test substances include the same as those
20 mentioned above.

(c) Analytical method for chemical structures of metabolites of xenobiotics and/or endogenous substrates:

For example, by analyzing the structural changes in
25 xenobiotics and/or endogenous substrates caused by exposure of the test substance to cells, it is possible to analyze the chemical structures of the xenobiotics and/or endogenous substrates (J.L. Napoli et al., Methods in Enzymology, Vol. 206, pp. 491-501, Ed. by M.R. Waterman et
30 al., Academic Press, 1991; H.K. Kroemer et al., Methods in Enzymology, Vol. 272, pp. 99-198, Ed. by M.R. Waterman et al., Academic Press, 1996).

Useful test substances include the same as those
35 mentioned above.

For example, by collecting conversions (what is called metabolites) of xenobiotics and/or endogenous substrates caused by exposure of the test substance to cells and purifying and separating them by an appropriate method, it is possible to prepare the metabolites of the xenobiotics and/or endogenous substrates (J.L. Napoli et al., Methods in Enzymology, Vol. 206, pp. 491-501, Ed. by M.R. Waterman et al., Academic Press, 1991).

(e) Analytical method for the inhibition of enzymes which metabolize xenobiotics and/or endogenous substrates:

For example, by exposing the test substance to cells, it is possible to analyze the inhibition of activity of the xenobiotics and/or endogenous substrates (J.L. Napoli et al., *Methods in Enzymology*, Vol. 206, pp. 491-501, Ed. by M.R. Waterman et al., Academic Press, 1991). Specifically, detection is possible by the inhibition of cytochrome P450 enzyme activity, a decrease in protein content, a decrease in mRNA, etc. Useful methods of detection include commonly known techniques, such as assays of enzyme activities corresponding to various types of P450, western blotting techniques corresponding to various P450 proteins, northern hybridization techniques corresponding to various types of P450 mRNA, and the RT-PCR method.

(f) Analytical method for the promotion of the activity of enzymes which metabolize xenobiotics and/or endogenous substrates:

For example, by exposing the test substance to cells and detecting the increase in the activity of enzymes which metabolize xenobiotics and/or endogenous substrates, the increase in the amount of the enzyme, the increase in the amount of transcription of the gene encoding the enzyme, or the like, it is possible to analyze the promotion of the activity of the xenobiotics and/or endogenous substrates (J. Rueff et al., Mutation Research, 353 (1996), 151-176). Specifically, it is possible by detecting the elevation of cytochrome P450 enzyme activity, an increase in protein content, or an increase in mRNA. Useful methods of detection include commonly known techniques, such as assays of enzyme activities corresponding to various types of P450, western blotting techniques corresponding to various P450 proteins, northern hybridization techniques corresponding to various types of P450 mRNA, and the RT-PCR method.

Useful test substances include the same as those mentioned above.

(g) Analytical method for cytotoxicity due to the metabolism of xenobiotics and/or endogenous substrates:

For example, by exposing the test substance to cells, it is possible to analyze the cytotoxicity due to the metabolism of the xenobiotics and/or endogenous substrates. Specifically, the analysis is achieved by observing cell morphological changes, viable cell count fluctuations, intracellular enzyme leakage, cell surface layer structural changes, intracellular enzyme fluctuations, etc. (D. Wu et al., Journal of Biological Chemistry, 271, (1996), 23914-23919).

Useful test substances include the same as those mentioned above.

(h) Analytical method for genotoxicity due to the

metabolism of xenobiotics and/or endogenous substrates:

For example, by exposing the test substance to cells and subjecting the cells to a chromosome aberration test, a micronucleus test, or the like, it is possible to analyze the genotoxicity due to the metabolism of xenobiotics and/or endogenous substrates. Furthermore, the analysis is possible by exposing the test substance to cells and subsequently evaluating the test substance altered by the cells using an appropriate evaluation system for a chromosome aberration test, a micronucleus test, a back mutation test, or the like (J. Rueff et al., Mutation Research, 353 (1996), 151-176; M.E. McManus et al., Methods in Enzymology, Vol. 206, pp. 501-508, Ed. by M.R. Waterman et al., Academic Press, 1991).

15

Useful test substances include the same as those mentioned above.

(i) Analytical method for carcinogenicity due to the metabolism of xenobiotics and/or endogenous substrates:

20

For example, by exposing the test substance to cells and subjecting the cells to a chromosome aberration test, DNA modification, or the like, it is possible to analyze the carcinogenicity due to the metabolism of xenobiotics and/or endogenous substrates. Furthermore, the analysis is possible by exposing the test substance to cells and evaluating the test substance altered by the cells using a carcinogenesis evaluation system with an appropriate chemical substance (J. Rueff et al., Mutation Research, 353 (1996), 151-176; K. Kawajiri et al., Cytochromes P450 metabolic and toxicological aspects, pp. 77-98, Ed. by C. Ioannides, CRC Press, 1996).

30

Useful test substances include the same as those mentioned above.

35

(j) Analytical method for mutagenicity due to the metabolism of xenobiotics and/or endogenous substrates:

For example, by exposing the test substance to cells and subjecting the cells to a chromosome aberration test, a micronucleus test, or the like, it is possible to analyze the mutagenicity due to the metabolism of xenobiotics and/or endogenous substrates. Furthermore, the analysis is possible by exposing the test substance to cells and subsequently evaluating the test substance altered by the cells using an appropriate evaluation system for a chromosome aberration test, a micronucleus test, a back mutation test, or the like (J. Rueff et al., Mutation Research, 353 (1996), 151-176).

Useful test substances include the same as those mentioned above.

(k) Analytical method for hepatotoxicity due to the metabolism of xenobiotics and/or endogenous substrates:

For example, by exposing the test substance to cells and observing the expression of cytotoxicity, or by exposing the test substance to cells, subsequently administering the test substance altered by the cells to another hepatocyte, a liver section, an extirpated liver, or a laboratory animal, and observing the changes caused thereby in cells, tissue, or living body, it is possible to analyze the hepatotoxicity due to the metabolism of xenobiotics and/or endogenous substrates.

Useful test substances include the same as those mentioned above.

(l) Analytical method for the hepatic action of xenobiotics and/or endogenous substrates:

For example, by exposing the test substance to cells, subsequently administering the test substance altered by

the cells to another hepatocyte, a liver section, an
extirpated liver, or a laboratory animal, and observing the
changes caused thereby in cells, tissue, or living body, it
is possible to analyze the expression of the action on the
5 liver.

Useful test substances include the same as those
mentioned above.

10 Abbreviations for bases and others used in the
present specification are based on abbreviations specified
by the IUPAC-IUB Commission on Biochemical Nomenclature or
abbreviations in common use in relevant fields. Some
examples are given below.

15

A : Adenine
T : Thymine
G : Guanine
C : Cytosine

20

The sequence ID numbers in the sequence listing of
the present specification are as follows:

[SEQ ID NO: 1]

Indicates a synthetic primer base sequence used for CYP1A1
25 in the RT-PCT method performed in Example 3 below.

[SEQ ID NO: 2]

Indicates another synthetic primer base sequence used for
CYP1A1 in the RT-PCT method performed in Example 3 below.

30

[SEQ ID NO: 3]

Indicates a synthetic primer base sequence used for CYP1A2
in the RT-PCT method performed in Example 3 below.

35 [SEQ ID NO: 4]

Indicates another synthetic primer base sequence used for

Pharmaceutical) supplemented with 10% fetal bovine serum. After 24 hours of cultivation, the SV 40 T antigen gene was introduced by the lipofection method using the plasmid pSV3Neo (P.J. Southern and P. Berg, J. Mol. Appl. Genet., 1, 327-341). For lipofection and subsequent procedures, a serum-free complete synthetic medium (ASF104, Ajinomoto) was constantly used as the culture medium. At 3 days after transfection, passage culture was conducted to promote the growth of hepatocytes, followed by 2 more days of cultivation and selection of neomycin-resistant cells. After 30 days of cultivation, a clone showing evident resistance to G418 was derived and designated as OUMS-29. This clone was believed to have been immortalized because it further grew over 300 generations in the ASF104 medium.

Example 2: Determination of the drug-metabolizing enzyme activity of the OUMS-29 culture

OUMS-29 cells becoming confluent after 5 to 7 days of cultivation on ASF104 medium were harvested, suspended in 0.1 M phosphate buffer (pH 7.6), and disrupted using an ultrasound generator; this suspension was used as the enzyme source to determine enzyme activity as described below.

(1) Cytochrome P450 reductase activity

Determinations were made basically by the method described in Biological Pharmacology, 37, 4111-4116, 1988. Specifically, cytochrome P450 reductase activity was determined on the basis of cytochrome C reduction in the presence of NADPH (reduced nicotinamide adenine dinucleotide phosphate) and an enzyme source of OUMS-29 origin with cytochrome C as the substrate. As a result, the enzyme source of OUMS-29 culture origin exhibited an enzyme activity of 8 units, taking the activity for reducing 1 nanomol of cytochrome C per milligram of protein per minute as 1 unit.

(2) Glucosyl transferase activity

Determinations were made basically by the method described in Biological Pharmacology, 37, 4111-4116, 1988. Specifically, the amount of 1-naphthol glucuronide produced was determined in the presence of UDP-glucuronic acid (Sigma) and an enzyme source of OUMS-29 origin with 1-naphthol (Sigma) as the substrate. As a result, the enzyme source of OUMS-29 culture origin exhibited an enzyme activity of 196 units, taking the activity for producing 1 picomol of 1-naphthol glucuronide per milligram of protein per minute as 1 unit.

(3) Mixed function oxidation (MFO) activity

Determinations were made basically by the method described in Biological Pharmacology, 42, 1307-1313, 1991. Specifically, the amount of product resulting from dealkylation of each substrate was determined in the presence of NADPH and an enzyme source of OUMS-29 origin with ethoxyresorufine (Sigma), pentoxyresorufine (Sigma), benzyloxyresorufine (Sigma) and methoxyresorufine (Sigma) as the substrates. As a result, the enzyme source of OUMS-29 culture origin exhibited enzyme activities of 0.25 units for ethoxyresorufine as the substrate, 0.47 units for pentoxyresorufine as the substrate, 0.38 units for benzyloxyresorufine as the substrate, and 0.32 units for methoxyresorufine as the substrate, respectively, taking the activity for producing 1 picomol of product per milligram of protein per minute as 1 unit.

Example 3: Expression of the cytochrome P450 gene

The expression of cytochrome P450 in the OUMS-29 culture can be analyzed by assessing the level of mRNA content by the commonly known RT-PCR method using DNA primers specific to different types of cytochrome P450. These primers can be prepared from the sequences of the

respective types of cytochrome P450 available from the Gene Bank database. The accession numbers at the Gene Bank are K03191 for CYP1A1, M55053 for CYP1A2, J02625 for CYP2E1, J04449 for CYP3A4, J04813 for CYP3A5, and D00408 for CYP3A7.

5 The individual primers used were 5'-ATGCTTTTCCCAATCTCCATGTGC and 5'-TTCAGGTCCTTGAAGGCATTCAGG for CYP1A1, 5'-GGAAGAACCCGCACCTGGCACTGT and 5'-AAACAGCATCATCTTCTCACTCAA for CYP1A2, and 5'-ATGGCTCTCATCCCAGACTTG and 5'-GGAAAGACTGTTATTGAGAGA for
10 CYP3A.

Regarding annealing conditions for the RT-PCR method, the annealing temperatures were 55°C for CYP1A1, 65°C for CYP1A2, 55°C for CYP3A, and 65°C for CYP2E1, the cycle
15 numbers being 28 to 36 cycles.

The OUMS-29 culture was cultured for 5 to 7 days; the cells becoming confluent were harvested, from which RNA was extracted using the RNAeasy kit (Quiagen). This RNA, along
20 with the previously determined primers specific to the respective types of cytochrome P450, was subjected to reverse transcription from mRNA and PCR using an one-step PCR kit (Takara Shuzo), after which it was separated using agarose gel and visualized with ultraviolet rays in the
25 presence of ethidium bromide. The results are shown in Fig. 1. Signals were detected at positions near 763 bp, predicted for CYP1A1, 1180 bp, predicted for CYP1A2, and 680 bp, predicted for CYP3A; the expression of the corresponding genes in the OUMS-29 culture was verified.

30

Example 4: Induction of expression of the cytochrome P450 gene

To OUMS-29 cells becoming confluent after cultivation for 5 to 7 days, 3-methylcholanthrene (3-MC) at final
35 concentrations of 0 to 10000 nM (Fig. 2), 0 to 50000 nM benzpyrene (BP) (Fig. 3), 0 to 25 mM phenobarbitone (PB)

(Fig. 4), or 0 to 1000 nM dexamethasone (DEX) (Fig. 5) was added, followed by cultivation for 1 more day. The cultured cells were separated, from which RNA was extracted using the method described above and subjected to RT-PCR.

5

Regarding annealing conditions for the RT-PCR method, the annealing temperatures were 55°C for CYP1A1, 65°C for CYP1A2, and 55°C for CYP3A, the cycle numbers being 28 to 36 cycles.

10

The cycle number for beta-actin, serving as a control, was 15 cycles.

In this operation, an actin competitive RT-PCR kit (Takara Shuzo) was used to correct the total mRNA content in each sample with reference to the mRNA content of beta-actin, which is expressed to the same extent in all tissues. The results are shown in Figs. 2 through 5. The expression of CYP1A1 was enhanced by the addition of 3-methylcholanthrene, benzpyrene, and phenobarbitone, the expression of CYP1A2 by the addition of 3-methylcholanthrene and benzpyrene, and the expression of CYP3A by the addition of dexamethasone; the OUMS-29 culture was verified to be capable of expressing the gene encoding cytochrome P450.

25

Industrial Applicability

The immortalized hepatocyte culture of human normal cell origin of the present invention, i.e., an immortalized hepatocyte culture of human origin which retains an enzyme activity involved in the metabolism of xenobiotics or the capability of expressing a gene encoding an enzyme involved in the metabolism of xenobiotics, is useful in screening for, for example, compounds having therapeutic/preventive effects on hepatic insufficiency or salts thereof.

35

Claims

1. An immortalized hepatocyte cell culture of human normal cell origin retaining an enzyme activity involved in the metabolism of xenobiotics in the liver or the capability of expressing a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver.
2. The cell culture according to Claim 1 wherein the enzyme activity is NADPH cytochrome P450 reductase activity, glucuronosyl transferase activity, ethoxyresorufine dealkylation activity, benzyloxyresorufine dealkylation activity, pentoxylresorufine dealkylation activity, methoxyresorufine dealkylation activity, flavin monooxygenase activity, epoxy hydratase activity, sulfotransferase activity or glutathione S-transferase activity.
3. The cell culture according to Claim 1 wherein the enzyme is NADPH cytochrome P450 reductase, NADPH cytochrome P450, flavin monooxygenase, epoxy hydratase, glucuronosyl transferase, sulfotransferase or glutathione S-transferase.
4. The cell culture according to Claim 3 wherein the NADPH cytochrome P450 is CYP1A1, CYP1A2 or CYP3A.
5. The cell culture according to Claim 1 wherein the cell culture is FERM BP-6328.
6. A method of producing the cell culture according to Claim 1, characterized by introduction of the T antigen gene of SV (simian virus) 40 origin into human normal hepatocytes.
7. The production method according to Claim 6 wherein the human normal hepatocytes are hepatocytes of human fetal origin.
8. A screening method for a compound or a salt thereof ① which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver or ② which inhibits or promotes the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the

liver, characterized by the use of the cell culture according to Claim 1.

9. A compound or a salt thereof ① which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver or ② which inhibits or promotes the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver, obtained by using the screening method according to Claim 8.

10. An analytical method for (a) enzymes involved in the metabolism of xenobiotics and/or endogenous substrates, (b) metabolic pathways for xenobiotics and/or endogenous substrates, (c) chemical structures of metabolites of xenobiotics and/or endogenous substrates, (d) inhibition of enzymes which metabolize xenobiotics and/or endogenous substrates, (e) promotion of the activity of enzymes which metabolize xenobiotics and/or endogenous substrates, (f) cytotoxicity due to the metabolism of xenobiotics and/or endogenous substrates, (g) genotoxicity due to the metabolism of xenobiotics and/or endogenous substrates, (h) carcinogenicity due to the metabolism of xenobiotics and/or endogenous substrates, (i) mutagenicity due to the metabolism of xenobiotics and/or endogenous substrates, (j) hepatotoxicity due to the metabolism of xenobiotics and/or endogenous substrates, or (k) hepatic action of xenobiotics and/or endogenous substrates, characterized by the use of the cell culture according to Claim 1.

11. A method of preparing metabolites of xenobiotics and/or endogenous substrates, characterized by the use of the cell culture according to Claim 1.

Abstract of the Disclosure

The present invention relates to a new immortalized hepatocyte culture of human (preferably human fetal) normal cell origin, a method of producing said culture, a screening method for a compound or a salt thereof which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver, or which inhibits or promotes the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver, or which inhibits or promotes the induction of expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver, characterized by the use of said culture, a compound which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver, a compound which inhibits or promotes the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver, or a compound which inhibits or promotes the induction of expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver, obtained using said screening method, or salts thereof.

The immortalized hepatocyte culture of human normal cell origin of the present invention is useful in, for example, screening for compounds or salts thereof having therapeutic/preventive effects on hepatic insufficiency .

PCT

世界知的所有権機関
国際事務局

特許協力条約に基づいて公開された国際出願



(51) 国際特許分類6 C12N 15/09, 5/10, C12Q 1/25, C12P 1/00	A1	(11) 国際公開番号 WO99/55853 (43) 国際公開日 1999年11月4日 (04.11.99)
(21) 国際出願番号 PCT/JP99/02224 (22) 国際出願日 1999年4月27日 (27.04.99) (30) 優先権データ 特願平10/119394 1998年4月28日 (28.04.98) JP (71) 出願人 (米国を除くすべての指定国について) 武田薬品工業株式会社 (TAKEDA CHEMICAL INDUSTRIES, LTD.) [JP/JP] 〒541-0045 大阪府大阪市中央区道修町四丁目1番1号 Osaka, (JP) (71) 出願人 ; および (72) 発明者 難波正義(NANBA, Masayoshi) [JP/JP] 〒700-0001 岡山県岡山市宿400-1 Okayama, (JP) (72) 発明者 ; および (75) 発明者 / 出願人 (米国についてのみ) 深谷憲一(FUKAYA, Kenichi) [JP/JP] 〒911-0804 福井県勝山市元町1丁目9-45 Fukui, (JP) 朝日 知(ASAHI, Satoru) [JP/JP] 〒565-0085 大阪府豊中市上新田1丁目24番A-307号 Osaka, (JP)	(74) 代理人 弁理士 朝比奈忠夫, 外(ASAHINA, Tadao et al.) 〒532-0024 大阪府大阪市淀川区十三本町2丁目17番85号 武田薬品工業株式会社 大阪工場内 Osaka, (JP) (81) 指定国 AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, 欧州特許 (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG), ARIPO特許 (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), ユーラシア特許 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM) 添付公開書類 国際調査報告書	
(54) Title: NOVEL IMMORTALIZED HEPATIC CELL LINE ORIGINATING IN HUMANS		
(54) 発明の名称 新規ヒト由来不死化肝細胞株		
(57) Abstract A novel immortalized hepatic cell line originating in normal human (preferably human fetal) cells; a process for producing this cell line; a method for screening compounds or salts thereof capable of inhibiting or promoting the activity of an enzyme participating in the metabolism of a biological foreign matter in the liver, inhibiting or promoting the expression of a gene encoding an enzyme participating in the metabolism of a biological foreign matter in the liver, or inhibiting or promoting the induction of the expression of a gene encoding an enzyme participating in the metabolism of a biological foreign matter in the liver, characterized by using the above-mentioned cell line; and compounds capable of inhibiting or promoting the activity of an enzyme participating in the metabolism of a biological foreign matter in the liver, compounds capable of inhibiting or promoting the expression of a gene encoding an enzyme participating in the metabolism of a biological foreign matter in the liver, compounds capable of inhibiting or promoting the induction of the expression of a gene encoding an enzyme participating in the metabolism of a biological foreign matter in the liver, or salts of these compounds obtained by the above screening method. The above cell line is useful in, for example, screening compounds having preventive/therapeutic effects on liver failure.		

Figure 1




Figure 2


3-MC




beta actin



CYP 1A1



CYP 1A2



nm

Figure 3




Figure 4





Figure 5



Declaration and Power of Attorney for Patent Application

特許出願宣言書及び委任状

Docket No. 2519 US0P

Japanese Language Declaration

日本語宣言書

私は、以下に記名された発明者として、ここに下記の通り宣言する：

As a below named inventor, I hereby declare that

私の住所、郵便の宛先そして国籍は、私の氏名の後に記載された通りである。

My residence, post office address and citizenship are as stated next to my name

下記の名称の発明について、特許請求範囲に記載され、且つ特許が求められている発明主題に関して、私は、最初、最先且つ唯一の発明者である（唯一の氏名が記載されている場合）か、或いは最初、最先且つ共同発明者である（複数の氏名が記載されている場合）と信じている。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A Human Derived Immortalized Liver Cell Line

上記発明の明細書はここに添付されているが、下記の欄がチェックされている場合は、この限りでない：

the specification of which is attached hereto unless the following box is checked

☐ _____ の日に出願され、
この出願の米国出願番号またはPCT国際出願番号は、
_____ であり、且つ
_____ の日に補正された出願（該当する場合）

☒ was filed on _____ Oct 19, 2000, April 27, 1999
as United States Application Number or
PCT International Application Number
US 09/673958, PCT/JP99/02224 and was amended on
_____ (if applicable)

私は、上記の補正書によって補正された、特許請求範囲を含む上記明細書を検討し、且つ内容を理解していることをここに表明する。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above

私は、連邦規則法典第37編規則1.56に定義されている、特許性について重要な情報を開示する義務があることを認める。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56

Japanese Language Declaration (日本語宣言書)

私は、ここに、以下に記載した外国での特許出願または発明者証の出願、或いは米国以外の少なくとも一国を指定している米国法典第35編第365条(a)によるPCT国際出願について、同第119条(a)-(d)項又は第365条(b)項に基づいて優先権を主張するとともに、優先権を主張する本出願の出願日より前の出願日を有する外国での特許出願または発明者証の出願、或いはPCT国際出願については、いかなる出願も、下記の枠内をチェックすることにより示した。

I hereby claim foreign priority under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application for which priority is claimed

Prior Foreign Application(s)
外国での先行出願

Priority Not Claimed
優先権主張なし

10-119394	Japan	28/04/1998	<input type="checkbox"/>
(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願日/月/年)	
(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願日/月/年)	<input type="checkbox"/>

私は、ここに、下記のいかなる米国仮特許出願についても、その米国法典第35編119条(e)項の利益を主張する。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below

(Application No.) (出願番号)	(Filing Date) (出願日)	(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------	-----------------------------	------------------------

私は、ここに、下記のいかなる米国出願についても、その米国法典第35編第120条に基づく利益を主張し、又米国を指定するいかなるPCT国際出願についても、その同第365条(c)に基づく利益を主張する。また、本出願の各特許請求の範囲の主題が、米国法典第35編第112条第1段に規定された態様で、先行する米国出願又はPCT国際出願に開示されていない場合においては、その先行出願の出願日と本国内出願日またはPCT国際出願日との間の期間中に入手された情報で、連邦規則法典第37編規則1.56に定義された特許性に関わる重要な情報について開示義務があることを承認する。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可、係属中、放棄)
(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可、係属中、放棄)

私は、ここに表明された私自身の知識に係わる陳述が真実であり、且つ情報と信ずることに基づく陳述が、真実であると信じられることを宣言し、さらに、故意に虚偽の陳述などを行った場合は、米国法典第18編第1001条に基づき、罰金または拘禁、若しくはその両方により処罰され、またそのような故意による虚偽の陳述は、本出願またはそれに対して発行されるいかなる特許も、その有効性に問題が生ずることを理解した上で陳述が行われたことを、ここに宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

400

SEQUENCE LISTING

<110> Takeda Chemical Industries, Ltd.

<120> Novel immortalized human hepatic cell line

<130> A98087

<150> JP 10-119394

<151> 1998-04-28

<160>

<210> 1

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 1

ATGCTTTTCC CAATCTCCAT GTGC 24

<210> 2

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 2

TTCAGGTCCT TGAAGGCATT CAGG 24

<210> 3

<211> 24

2/3

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 3

GGAAGAACCC GCACCTGGCA CTGT

24

<210> 4

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 4

AAACAGCATC ATCTTCTCAC TCAA

24

<210> 5

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 5

ATGGCTCTCA TCCCAGACTT G

21

<210> 6

<211> 21

3/3

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 6

GGAAAGACTG TTATTGAGAG A

21